Hims & Hers Health is a digital healthcare platform that provides access to treatments for sexual health, hair loss, and weight management through a subscription model. The company reached $1.48 billion in revenue in 2024, a 69% increase over the prior year, and turned a full-year GAAP profit of $126 million. It now serves 2.2 million subscribers, with growth accelerating sharply as it expands into the massive market for weight loss medications.
The investment thesis on Hims & Hers is that its massive scale and direct relationship with patients allow it to turn generic drugs into high-margin, personalized brands that traditional pharmacies cannot easily copy. More specifically, four things need to be true:
We think Hims & Hers is successfully evolving from a simple pill distributor into a durable healthcare brand that patients actually trust and prefer. The recent launch of compounded weight loss medications at a fraction of the cost of brand-name versions provides a massive new growth engine that is already showing up in the numbers.
Hims & Hers stock jumped early on and has soared lately after a brief dip. The company has gone from a small startup to a massive business by selling popular health treatments directly to millions of people online. It is now making a real profit as it starts selling weight loss drugs to even more customers.
What does it do?
Hims & Hers Health is a hypergrowth business that earns money by selling recurring subscriptions for health and wellness treatments directly to consumers. Customers use a website or app to consult virtually with licensed medical providers who can prescribe medications for conditions like hair loss, anxiety, sexual health, and weight management. The company manages the entire experience, from the initial consultation to the monthly shipment of medications from its own pharmacies. Because it bypasses traditional retail pharmacies and insurance companies, it can offer transparent, flat-rate pricing that is often cheaper for patients than a standard co-pay.
Where does revenue come from?
Almost all revenue comes from monthly online subscriptions for prescription and over-the-counter health products. The business is divided into Hims (focused on men) and Hers (focused on women), with both brands offering similar categories of care. Most revenue is generated in the United States, where the digital-first model has gained the most traction.
Revenue by Geography
Who are its customers?
Hims & Hers Health serves 2.2 million active subscribers who pay an average of $147 per order as of late 2024. This customer base grew 45% last year, driven by younger adults who prefer the convenience of virtual care over visiting a doctor in person. More than 1 million of these subscribers now use personalized solutions, which are customized dosages or combinations of ingredients tailored to their specific needs. Monthly online revenue per average subscriber reached $67 in the third quarter of 2024, a 24% increase that shows customers are spending more on the platform as new categories like weight loss are introduced.
What gives it staying power?
The company has staying power because more than 50% of its users are on personalized plans that cannot be easily filled at a local CVS or Walgreens. High switching costs emerge as patients find a specific custom formulation that works for them, creating a more durable relationship than a simple generic prescription.
Where is it headed?
The company is making a massive strategic bet on the weight loss market by offering compounded GLP-1 injections at a $199 monthly price point. Management believes this offering can scale to tens of millions of Americans who are currently priced out of brand-name weight loss drugs. This expansion is designed to turn Hims into a comprehensive health platform rather than just a specialist in a few categories.
Revenue is in a state of hypergrowth, with a 69% increase in 2024 followed by a 111% surge in Q1 2025. This acceleration is rare for a company of this scale and suggests the weight loss launch is finding immediate demand.
Cash generation is excellent, with $200 million in free cash flow produced in 2024 alongside a $126 million GAAP net profit. This proves the business can grow rapidly without needing outside capital, as the high 68% gross margins more than cover marketing costs.
The balance sheet is remarkably clean for a growth company, carrying virtually no long-term debt and a significant cash position. This financial strength allows management to invest aggressively in pharmacy infrastructure and new product launches without risking the company's stability.
Hims & Hers has successfully transitioned into a highly profitable compounding machine that grows faster than its customer acquisition costs.
Subscriber count reached 2.2 million in 2024, a 45% increase that is accelerating as the company expands into weight loss. The shift toward personalized treatments is also lifting average order values to $147, proving that customers are willing to pay for more than just basic generics.
The single most important risk is a change in the supply or regulatory status of GLP-1 medications. If brand-name drug shortages end or the FDA restricts compounded versions, Hims could lose a significant portion of its newest growth engine.
The digital health and direct-to-consumer pharmacy market is roughly $100 billion today and growing 20% annually, on track to exceed $200 billion by 2028. This is a highly attractive industry because health spending is non-discretionary, and the shift from physical to digital pharmacies is a long-term trend. Pricing power is structural for companies that can offer a better user experience and cheaper access than the traditional insurance-based system. Hims & Hers is currently a leader in the specialized DTC segment, giving it a significant head start in scale and brand recognition.
The market for digital healthcare is becoming increasingly competitive as traditional pharmaceutical companies and tech giants enter the space. While barriers to entry for a simple website are low, building a licensed pharmacy infrastructure at scale is difficult. Competition is currently focused on the weight loss category, where pricing is becoming a primary battleground.
Ro is the most direct threat, matching Hims on price and product breadth across nearly every major health category. Amazon Pharmacy poses a different risk by integrating prescriptions into its existing Prime membership, which could commoditize basic generics. Eli Lilly's move to sell its own weight loss drugs directly to consumers through LillyDirect bypasses the middleman and could hurt third-party platforms.
Hims & Hers is currently gaining share by moving faster than legacy healthcare players and offering lower prices on compounded medications.
The primary source of protection for Hims & Hers is its brand and the data it uses to create personalized treatments. By moving more than 50% of its users onto custom formulations, Hims creates a "lock-in" that traditional pharmacies cannot easily replicate. Patients who find a specific dosage or ingredient mix that works for them are much less likely to switch to a generic competitor.
The 68% gross margins and 2.2 million loyal subscribers prove that this advantage is real and not just a result of a marketing boom. High retention rates among long-term subscribers suggest that once a customer enters the ecosystem, the cost to keep them is low. The combination of high margins and recurring revenue is a strong signal of a functional moat.
The moat is currently strengthening as the company builds out its own compounding pharmacies and increases its personalized product mix.
Revenue grew 69% in 2024 while turning the company GAAP profitable.
Generated $200M in FCF in 2024 while funding new GLP-1 launch.
Andrew Dudum is a co-founder and remains a significant shareholder.
Capital Allocation Track Record
Andrew Dudum has demonstrated exceptional strategic judgment by pivoting Hims from a simple marketing site into a profitable, infrastructure-heavy healthcare platform. He successfully guided the company through the transition to GAAP profitability in 2024 without slowing down its hypergrowth trajectory. His decision to aggressively enter the weight loss market with a lower-priced, compounded offering shows a willingness to disrupt traditional healthcare pricing to win long-term market share.
The investment thesis is highly dependent on Andrew Dudum's vision, but the company has built a deep bench of experienced executives in medical and financial roles. While he remains the primary driver of strategy, the successful build-out of a national pharmacy network suggests the company is no longer just a "key-person" risk. The dual-class share structure gives him significant control, which has so far been used to focus on long-term growth and capital discipline.
We expect revenue to grow from $2.9B in FY2026 to $5.8B in FY2031 (~15% CAGR), with EPS growing from $-0.12 to $2.00. Personalized weight loss treatments and GLP-1 medications are driving a massive new wave of long-term subscribers. Marketing costs as a percentage of sales drop significantly as the company shifts from acquiring new users to retaining existing ones on recurring plans. EPS grows much faster than revenue because the platform's fixed infrastructure is already built, allowing new sales to generate higher profit. Operating margin expected to reach ~20% by FY2031.
Scalable weight loss program reaches mass-market adoption. If the $199 compounded GLP-1 offering becomes the standard for price-sensitive patients, it could quadruple the company's total subscriber base.
Personalization mix rises above 70% of subscribers. Higher personalization increases customer retention and lifts gross margins by reducing the threat from cheap, generic-only competitors.
Category expansion into primary care or mental health. Leveraging the existing 2.2 million subscribers to launch new specialties would lower customer acquisition costs across the entire platform.
Regulatory changes restrict the use of compounded GLP-1s. If the FDA ends the shortage designation for brand-name weight loss drugs, Hims could lose its ability to sell its most popular new product.
Marketing costs rise as competition for weight loss intensifies. A price war or increased advertising spend from competitors like Ro or Eli Lilly could squeeze profit margins.
Supply chain disruptions at proprietary compounding pharmacies. Any manufacturing or safety issue at its own facilities would cause immediate reputational damage and subscriber churn.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach (price-to-earnings applied to next year's earnings). It fits Hims & Hers because the company has reached a critical inflection point where it is generating consistent positive free cash flow and GAAP (generally accepted accounting principles) profitability is becoming the primary signal for investors, rather than just raw revenue growth.
FY2027 EPS of $0.47 multiplied by a 75x multiple gives a per-share fair value of $35. A 75x multiple sits at a premium to mature healthcare peers like Teladoc (15x) but below high-growth fintech platforms like Affirm (85x), which is justified by the massive addressable market for obesity and Hims' 40% plus growth rate. We used the deterministic engine's FY2027 EPS of $0.47 as the basis, which provides a clean "post-ramp" look at the business after the one-time non-cash losses recorded in early 2026.
A peer-anchored EV/Revenue cross-check produces a fair value of $36, within 3% of our primary result and confirming the valuation. Applying a 3.0x revenue multiple to the $2.9B FY2026 revenue guidance midpoint yields an Enterprise Value (total business value) of $8.7B; after subtracting the $0.91B in net debt and dividing by 223 million shares, we arrive at $34.93. The close alignment between the revenue and earnings frameworks suggests the current market price is efficiently capturing the company's high-growth but margin-pressured trajectory.
We're assuming the weight-loss subscriber base remains resilient even after brand-name drug shortages are resolved. While the initial surge was driven by supply gaps, the Hims & Hers "Wegovy Pill" and personalized dosages offer a convenience and price point that brand-name injections do not, which should support retention among the nearly 2.6 million total subscribers.
We're assuming gross margins stabilize around 65% as the company scales its own pharmacy and compounding facilities. This is a step down from the historical 75% plus range, reflecting the higher cost of ingredients for weight-loss medications and the initial investments in vertical integration, but remains well above traditional retail pharmacy benchmarks.
We're assuming the company can sustain 35% revenue growth through FY2027 by expanding into new categories like testosterone and multi-cancer testing. The recent launch of "Testosterone Rx+" and the Galleri multi-cancer test suggests management is aggressively diversifying the platform to reduce reliance on any single medical category or regulatory loophole.
The single biggest risk is a regulatory shift that ends the legal shortage status of GLP-1 medications like Ozempic and Wegovy. This would likely force the company to stop selling its high-margin compounded semaglutide, compressing the forward multiple from 75x to roughly 40x and knocking nearly $16 off the per-share fair value. Investors should watch the FDA Orange Book for "Resolved" status on these specific drug shortages.
Bear case ($22): The FDA officially declares the GLP-1 (weight-loss drug) shortage over, ending the legal window for selling compounded alternatives; or Gross margins drop below 60% as the company is forced to shift from proprietary compounded meds to lower-margin brand-name drugs.
Bull case ($54): Subscriber growth in the weight-loss vertical exceeds 40% annually through 2027 while maintaining a $50+ monthly revenue per user; or The company demonstrates significant operating leverage, with marketing expenses falling below 30% of revenue as the brand becomes a household name.
Clearthesis wrote this report from 39 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning bullish because Hims and Hers is successfully turning affordable generic weight loss drugs into a high-margin, scalable subscription business. By cutting out the middleman and selling directly to patients, the company has grown to over two million subscribers and achieved a GAAP profit of 126 million dollars.
Skeptics think that the company relies too heavily on popular trends that could fade as traditional pharmaceutical access improves. The business model depends on maintaining a unique advantage in selling personalized versions of generic drugs that may eventually face much stiffer competition from established pharmacy and healthcare incumbents.